Bristol Myers Squibb

AbbVie stock plunges after schizophrenia drug trial failure

Bristol Myers Squibb Q3 revenue soars 8%, new drug approved

LBT Innovations lands first US sale of APAS Independence instrument

LBT Innovations erzielt ersten Verkauf des APAS Independence Instruments in den USA.

Bristol Myers Squibb shares surge after FDA approval of new schizophrenia drug

Bristol-Myers Squibb (NYSE:BMY) posts 9% revenue jump in Q2 2024

Bristol Myers Squibb (NYSE:BMY) warns shareholders against low-ball tender offer

Mirati Therapeutics (NASDAQ:MRTX) merges with Bristol-Myers Squibb in $4.8B deal